OSR Holdings files audited FY2024 financials for Legacy OSR; net loss widens to ₩14.1B

OSR Holdings, Inc.

Net loss of ₩14.09B (₩7,466 per share) for 2024 vs ₩13.61B loss in 2023 on revenue of ₩4.82B (+8% YoY).
Operating loss increased to ₩15.95B from ₩14.78B; SG&A expenses grew to ₩17.05B.
Total assets ₩257.6B, equity ₩210.5B; cash and equivalents dropped to ₩502M from ₩697M.
Key subsidiaries: VAXIMM (Switzerland, biotech), RMC (medical devices, Korea), Darnatein (biotech, Korea).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.